A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 May 2018
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms EuroCTO
- 02 May 2018 Primary endpoint (Quality of Life) has been met, according to the results published in the European Heart Journal.
- 02 May 2018 Results published in the European Heart Journal.
- 31 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018.